Showing results (21-30 of 122) with videos related to

Sort By:
Pageof 13
Urologic Oncology|March 26, 2021
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?Giuseppe Basile, Filippo Pederzoli, Marco Bandini, et al.
Clinical Genitourinary Cancer|June 22, 2016
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-AnalysisAndrea Necchi, Gregory R Pond, Daniele Raggi, et al.
Urologic Oncology|November 29, 2021
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpointsGiuseppe Basile, Marco Bandini, Daniele Raggi, et al.
Urologic Oncology|August 16, 2022
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping reviewTiago Costa de Padua, Marco Moschini, Alberto Martini, et al.
Critical Reviews in Oncology/Hematology|July 4, 2016
Immunotherapy advances in uro-genital malignanciesRaffaele Ratta, Roberta Zappasodi, Daniele Raggi, et al.
Clinical Genitourinary Cancer|September 27, 2020
Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard TreatmentDaniele Raggi, Marco Bandini, Patrizia Giannatempo, et al.
Clinical Genitourinary Cancer|October 4, 2016
Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized StudiesAndrea Necchi, Rosalba Miceli, Karima Oualla, et al.
Cancer Treatment Reviews|August 8, 2022
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysisGiuseppe Fallara, Daniele Robesti, Luigi Nocera, et al.
European Urology Oncology|June 17, 2023
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic ReviewEmanuele Crupi, Tiago Costa de Padua, Laura Marandino, et al.
BJU International|July 9, 2023
The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trialsDaniele Robesti, Luigi Nocera, Federico Belladelli, et al.
Pageof 13